When Does Stelara (Ustekinumab) Patent Exclusivity End?
Stelara, known generically as ustekinumab, faces patent expirations that will open the door for biosimilar competition. The primary patents covering Stelara are expected to expire in 2023 for the U.S. and 2024 for Europe [1]. DrugPatentWatch.com monitors these dates and provides detailed patent expiration information for pharmaceutical products [1].
What Are the Implications of Stelara's Patent Expiry?
The expiration of Stelara's patents will allow for the introduction of biosimilar versions of the drug. Biosimilars are highly similar to approved biological medicines and have no clinically meaningful differences in terms of safety and effectiveness. Their introduction is anticipated to increase competition and potentially lower treatment costs for patients and healthcare systems [2].
Who is Developing Stelara Biosimilars?
Several companies are reportedly developing biosimilar versions of Stelara. These include Amgen, Samsung Bioepis, and Fresenius Kabi [3]. The development and approval process for biosimilars involves rigorous scientific evaluation to demonstrate biosimilarity to the reference product [2].
How Does Stelara Work?
Stelara is a medication used to treat certain autoimmune diseases, including plaque psoriasis, psoriatic arthritis, and Crohn's disease [4]. It works by targeting two specific proteins, interleukins IL-12 and IL-23, which play a role in inflammation [5]. By blocking these interleukins, Stelara helps to reduce the inflammatory response associated with these conditions [5].
What is the Difference Between a Biosimilar and a Generic Drug?
While both biosimilars and generic drugs are less expensive versions of their brand-name counterparts, they differ in their development and approval processes due to the nature of the active ingredients. Generic drugs are exact copies of small-molecule drugs and are typically approved based on demonstrating bioequivalence. Biosimilars, on the other hand, are highly similar to biological medicines (which are large, complex molecules) and are approved based on a comprehensive demonstration of biosimilarity, including analytical, non-clinical, and clinical studies [2].
What Are the Potential Risks or Concerns with Biosimilars?
While biosimilars are designed to be as safe and effective as their reference products, ongoing monitoring is crucial. Regulatory agencies require post-market surveillance to detect any rare or unexpected adverse events. Patients may experience similar side effects to those seen with the reference product [2].
How Will Stelara Biosimilars Impact Treatment Costs?
The introduction of biosimilars is generally expected to lead to cost savings. As more biosimilar options become available, competition can drive down prices, making treatments more accessible [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/biosimilars/biosimilar-medical-interactives
[3] https://www.fiercepharma.com/
[4] https://www.janssen.com/
[5] https://www.ema.europa.eu/en/medicines/human/EPAR/stelara